Literature DB >> 15308580

Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2.

Shu Wakino1, Koichi Hayashi, Takeshi Kanda, Satoru Tatematsu, Koichiro Homma, Kyoko Yoshioka, Ichiro Takamatsu, Takao Saruta.   

Abstract

Although peroxisome proliferator-activated receptor gamma (PPARgamma) ligands have an antihypertensive effect in vivo, the precise mechanism has not been fully elucidated. We examined their effects on Rho/Rho kinase pathway, a key regulator of vascular tone. In cultured rat aortic smooth muscle cells (RASMC), Rho kinase stimulated by angiotensin II was suppressed by the pretreatment with pioglitazone and troglitazone, and these effects were explained by the inhibition of the Rho translocation to the cell membrane. We evaluated the role of Vav, a GTP/GDP exchange factor upregulating Rho kinase activity, and Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2), a protein tyrosine phosphatase that dephosphorylated Vav and subsequently inactivated Rho kinase. Both pioglitazone and troglitazone upregulated SHP-2, particularly in the cytosolic fraction, and the SHP-2-bound Vav, and reduced the phosphorylation of Vav. Furthermore, 4-week treatment with pioglitazone lowered systolic blood pressure in spontaneously hypertensive rats (SHR) and suppressed the Rho/Rho kinase activity in aortic tissues isolated from SHR. Consistently, the expression of SHP-2 was upregulated in vascular tissues from pioglitazone-treated SHR. The phosphorylated Vav was increased in SHR, compared with that in normotensive Wistar-Kyoto rats (WKY), which was mitigated by pioglitazone. Finally, both basal and angiotensin II-stimulated levels of Rho kinase activity were greater in RASMC from SHR than those from WKY, and the enhanced Rho kinase activity was blocked by pioglitazone or troglitazone in both strains. Collectively, PPARgamma ligands inhibit the Rho/Rho kinase pathway through upregulation of cytosolic SHP-2 expression and inactivation of Vav, and may contribute to the hemodynamic, in addition to metabolic, action in hypertensive metabolic syndrome. The full text of this article is available online at http://circres.ahajournals.org.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308580     DOI: 10.1161/01.RES.0000142313.68389.92

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  39 in total

Review 1.  Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders.

Authors:  Pitchai Balakumar; Sonam Kathuria
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 2.  The role of Src homology 2 containing protein tyrosine phosphatase 2 in vascular smooth muscle cell migration and proliferation.

Authors:  Machender R Kandadi; Matthew S Stratton; Jun Ren
Journal:  Acta Pharmacol Sin       Date:  2010-09-27       Impact factor: 6.150

Review 3.  Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.

Authors:  Hong Sheng Cheng; Wei Ren Tan; Zun Siong Low; Charlie Marvalim; Justin Yin Hao Lee; Nguan Soon Tan
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

4.  Angiotensin II type-1 receptor regulates RhoA and Rho-kinase/ROCK activation via multiple mechanisms. Focus on "Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells".

Authors:  Keita Kimura; Satoru Eguchi
Journal:  Am J Physiol Cell Physiol       Date:  2009-09-09       Impact factor: 4.249

Review 5.  The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.

Authors:  P C Manoria; H K Chopra; S K Parashar; A L Dutta; Brian Pinto; Ajit Mullasari; Samir Prajapati
Journal:  Indian Heart J       Date:  2013-11-25

Review 6.  The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation.

Authors:  Marilyn J Cipolla; David S Liebeskind; Siu-Lung Chan
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-10       Impact factor: 6.200

7.  A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons.

Authors:  John Dill; Ankur R Patel; Xiao-Li Yang; Robert Bachoo; Craig M Powell; Shuxin Li
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

8.  Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes.

Authors:  Servio H Ramirez; David Heilman; Brenda Morsey; Raghava Potula; James Haorah; Yuri Persidsky
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

9.  Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARγ and RhoA/Rho-kinase.

Authors:  Christopher J Pelham; Pimonrat Ketsawatsomkron; Séverine Groh; Justin L Grobe; Willem J de Lange; Stella-Rita C Ibeawuchi; Henry L Keen; Eric T Weatherford; Frank M Faraci; Curt D Sigmund
Journal:  Cell Metab       Date:  2012-10-03       Impact factor: 27.287

10.  15-Deoxy-Delta-Prostaglandin J(2) Upregulates the Expression of LPS-Induced IL-8/CXCL8 mRNA in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats.

Authors:  Jung Hae Kim; Hee Sun Kim
Journal:  Immune Netw       Date:  2009-04-30       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.